TCGA-68-A59J-01A-21R-A26W-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- INTERFERON_ALPHA_RESPONSE+0.530
- INTERFERON_GAMMA_RESPONSE+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.410
- MYC_TARGETS_V1+0.310
- TNFA_SIGNALING_VIA_NFKB+0.290
- WNT_BETA_CATENIN_SIGNALING+0.270
- HEDGEHOG_SIGNALING+0.250
- G2M_CHECKPOINT+0.240
- HYPOXIA+0.220
Top 10 suppressed
- TGF_BETA_SIGNALING-0.340
- ANGIOGENESIS-0.290
- APICAL_JUNCTION-0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.240
- BILE_ACID_METABOLISM-0.160
- COAGULATION-0.160
- PANCREAS_BETA_CELLS-0.150
- PEROXISOME-0.150
- UV_RESPONSE_DN-0.140
- HEME_METABOLISM-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20110226.TNBC | — | E | 0.753 |
| 2 | TCGA-AO-A0J6-01A-11R-A034-07 | — | E | 0.747 |
| 3 | TCGA-DK-AA6Q-01A-11R-A39I-07 | — | — | 0.737 |
| 4 | TCGA-ZF-AA4W-01A-12R-A38B-07 | — | — | 0.735 |
| 5 | TCGA-B6-A0IJ-01A-11R-A034-07 | — | E | 0.733 |
| 6 | SRR8518188 | — | D | 0.733 |
| 7 | TCGA-AR-A0U0-01A-11R-A109-07 | — | E | 0.730 |
| 8 | TCGA-E2-A14N-01A-31R-A137-07 | — | E | 0.725 |
| 9 | SRR8518159 | — | E | 0.721 |
| 10 | 20100125.TNBC | — | E | 0.720 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.460 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.410 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.240 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.180 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.160 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.160 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.120 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |